	1267565
RECEIVE	
FORM D UNITED STATES REGULTS REGULTS	OMB APPROVAL OMB NUMBER: 3235-0076
SECURITIES AND EXCHANGE COMMISSION	Expirés: April 30, 2008 Estimated average burden hours per response16.00
NOV 1 9 2007 TO SALE OF SECURITIES PURSUANT TO	SEC USE ONLY
SECTION 4(6), AND/OR	Prefix Scrial
182 SUNIFORM LIMITED OFFERING EXEMPTION	DATE RECEIVED
Name of Offering (check if this is an amendment and name has changed, and indicate change.)	<u> </u>
Convertible Notes and Warrants	
Filing Under (Check box(es) that apply): □ Rule 504 □ Rule 505 ■ Rule 506 □ Section Type of Filing: ■ New Filing □ Amendment	4(6) □ ULOE
A. BASIC IDENTIFICATION DATA	
Enter the information requested about the issuer	
Name of Issuer (check if this is an amendment and name has changed, and indicate change.)	07083695
Collegium Pharmaceutical, Inc.	
· ·	
Address of Executive Offices (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
Address of Executive Offices (Number and Street, City, State, Zip Code) 400 Highland Corporate Drive, Cumberland, RI 02864	Telephone Number (Including Area Code) 401-762-2000
400 Highland Corporate Drive, Cumberland, RI 02864 Address of Principal Business Operations (if (Number and Street, City, State, Zip Code)	401-762-2000
400 Highland Corporate Drive, Cumberland, RI 02864 Address of Principal Business Operations (if different from Executive Offices) (Number and Street, City, State, Zip Code)	401-762-2000
400 Highland Corporate Drive, Cumberland, RI 02864 Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) different from Executive Offices) Brief Description of Business: Developer of drugs and other therapeutic compounds Type of Business Organization	401-762-2000 Telephone Number (Including Area Code)
Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) different from Executive Offices) Brief Description of Business: Developer of drugs and other therapeutic compounds Type of Business Organization © corporation	401-762-2000
Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) different from Executive Offices) Brief Description of Business: Developer of drugs and other therapeutic compounds Type of Business Organization corporation business trust Imited partnership, already formed Imited partnership, to be formed	401-762-2000 Telephone Number (Including Area Code)
Address of Principal Business Operations (if (Number and Street, City, State, Zip Code) different from Executive Offices) Brief Description of Business: Developer of drugs and other therapeutic compounds Type of Business Organization corporation business trust Dimited partnership, already formed I limited partnership, to be formed	### THOMSON

GENERAL INSTRUCTIONS

Federal:

Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D or Section 4(6), 17 CFR 230.501 et seq. or 15 USC 77d(6).

When To File: A notice must be filed no later than 15 days after the first sale of securities in the offering. A notice is deemed filed with the U.S. Securities and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given below or, if received at that address after the date on which it is due, on the date it was mailed by United States registered or certified mail to that address.

When to File: U.S. Securities and Exchange Commission, 100 F Street, N.E., Washington, D.C. 20549.

Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

Information Required: A new filing must contain all information requested. Amendments need only report the name of the issuer and offering, any changes thereto, the information requested in Part C, and any material changes from the information previously supplied in Parts A and B. Part E and the Appendix need not be filed with the SEC.

Filing Fee: There is no federal filing fee.

State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for sales of securities in those states that have adopted ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the Securities Administrator in each state where sales are to be, or have been made. If a state requires a payment of a fee as a precondition to the claim for the exemption, a fee in the proper amount shall accompany this form. This notice shall be filed in the appropriate states in accordance with state law. The Appendix to the notice constitutes a part of this notice and must be completed.

Failure to file notice in the appropriate states will not result in a loss of the federal exemption. Conversely, failure to file the appropriate federal notice will not result in a loss of an available state exemption unless such exemption is predicated on the filing of a federal notice.

		A. BASIC IDENT	IFICATION DATA		
Enter the information requested for the Each promoter of the issuer, if Each beneficial owner having the Each executive officer and direct Each general and managing page.	the issuer has be the power to vot ector of corporat	e or dispose, or direct the e issuers and of corporate	vote or disposition of, 10		ass of equity securities of the issuer; hip issuers; and
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	■ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	· · ·				
Heffernan, Michael					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)	,	
	·	·			
c/o Collegium Pharmaceutical, Inc., 400					
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Rothman, Michael					
Business or Residence Address	(Number and	Street, City, State, Zip Co	sde)		
c/o Collegium Pharmaceutical, Inc., 400	Highland Cor	porote Brive Cumberlo	and D1 07864		
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	■ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	<u> </u>	Beneficial Office	Excessive Onioci	<u> </u>	Oction with the transfer of th
,					
Hirsch, Mark	01	to a Charles Time Co	1-1		
Business or Residence Address	(Number and S	Street, City, State, Zip Co	ue)		
c/o Collegium Pharmaceutical, Inc., 400	Highland Cor	porate Drive, Cumberla	nd, R1 02864		
Check Box(es) that Apply:	☐ Promoter	□ Beneficial Owner	□Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Hirsh, Jane					
Business or Residence Address	(Number and S	street, City, State, Zip Co	de)		
4.00 10 10 10 10 10 10 10 10 10 10 10 10 1			1 DI 000/4		
c/o Collegium Pharmaceutical, Inc., 400 Check Box(es) that Apply:		Deneficial Owner □ Beneficial Owner	Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	□ Promoter	☐ Beneficial Owner	Li Executive Officer	Director	General and/or Managing Partner
1 th Name (Dast name 113t it morroum)					
Fortune, Patrick J.					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
c/o Collegium Pharmaceutical, Inc., 400	Highland Cor	porate Drive, Cumberla	and, RI 02864		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	■ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Cincheal: Matthew					
Strobeck, Matthew Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
c/o Collegium Pharmaceutical, Inc., 400					
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Boston Millennia Partners II Limited P	artnership				
Business or Residence Address	(Number and	Street, City, State, Zip C	ode)		
30 Rowes Wharf, Suite 500, Boston, MA	. 02110				
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)	a Homotel	a Denoncial Owner	L'ACCOUVE OTHOE	- Director	C. Ocuden mimor talmingling t mitter
•					
Boston Millennia Partners GmbH & Co		Parant City Dark 72: C	ada)		
Business or Residence Address	(Number and	Street, City, State, Zip C	ode)		
30 Rowes Wharf, Suite 500, Boston, MA	02110				

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

		A. BASIC IDENT	IFICATION DATA		
Each executive officer and dire Each general and managing part	the issuer has be the power to vot ector of corporat	e or dispose, or direct the e issuers and of corporate	vote or disposition of, 10		lass of equity securities of the issuer; ship issuers; and
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	□ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
NMJ, LP					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ide)		
	•		•		
c/o Collegium Pharmaceutical, Inc., 400		<u> </u>			
Check Box(es) that Apply:	□ Promoter	■ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Island View Investors, LLC					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ide)		
c/o Collegium Pharmaceutical, Inc., 400	Highland Cor	porate Drive Cumberla	nd R1 02864		
Check Box(es) that Apply:	☐ Promoter	■ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					2 34444
Westfield Life Sciences Fund II L.P. Business or Residence Address	Alumber and	Street, City, State, Zip Co			
Dusmicss of Residence Address	(Ivanioci mia	onicet, eny, otate, 2sp co	ac)		
One Financial Center, 24th floor, Boston	, MA 02111				
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Business or Residence Address	(Number and	Street, City, State, Zip Co	rde)		
Datalies of Residence (1991)	(011, 0111, 01110, 21p 00			
					· · · · · · · · · · · · · · · · · · ·
Check Box(es) that Apply:	□ Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)	• •	
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	☐ Director	General and/or Managing Partner
Full Name (Last name first, if individual)					
Business or Residence Address	(Number and	Street, City, State, Zip Co	nde)		
Dusmess of Residence / Idaless	(i tunioci uno	ouver, eny, andre, zip er	, de la companya de l		
Check Box(es) that Apply:	☐ Promoter	☐ Beneficial Owner	☐ Executive Officer	□ Director	☐ General and/or Managing Partner
Full Name (Last name first, if individual)					
Business or Residence Address	(Number and	Street, City, State, Zip Co	ode)		

	B. INFORMATION ABOUT OFFERING		
		Yes	No
1.	Has the issuer sold, or does the issuer intend to sell, to non-accredited investors in this offering?	Ö	E)
2.	Answer also in Appendix, Column 2, if filing under ULOE. What is the minimum investment that will be accepted from any individual?	\$ n/a	
2.	what is the minimum investment that will be accepted from any marriedar.	Yes	Nο
3.	Does the offering permit joint ownership of a single unit?	•	CI
4.	Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.		
Full	Name (Last name first, if individual)		
	iness or Residence Address (Number and Street, City, State, Zip Code)		
Đusi	mess of Residence Address (Number and Street, City, State, Zip Code)		
Nam	ne of Associated Broker or Dealer		
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers (Check "All States" or check individual States)	All States	
•	,		(ID)
_ {I _ (I	AL] _ [AK] _ [AZ] _ [AR] _ [CA] _ [CO] _ [CT] _ [DE] _ [DC] _ [FL] _ [GA] [IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] [MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK] [RI] _ [SC] _ [SD] _ [TN] _ [TX] _ [UT] _ [VT] _ [VA] _ [WA] _ [WV] _ [WI]	_ [HI] _ [MS] _ [OR] _ [WY]	_ (ID) _ (MO) _ [PA] _ [PR]
Full	name (Last name first, if individual)		
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)		
Nam	ne of Associated Broker or Dealer		
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	All States	
1] _ 1] _ 1] _ 1] _	IL] _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ [ID] _ [MO] _ [PA] _ [PR]
Full	Name (Last name first, if individual)		
Busi	iness or Residence Address (Number and Street, City, State, Zip Code)		
Nam	ne of Associated Broker or Dealer		
State	es in which Person Listed Has Solicited or Intends to Solicit Purchasers		
	(Check "All States" or check individual States)	All States	
4] _ 1] _ 1] _ 1] _	IL) _ [IN] _ [IA] _ [KS] _ [KY] _ [LA] _ [ME] _ [MD] _ [MA] _ [MI] _ [MN] MT] _ [NE] _ [NV] _ [NH] _ [NJ] _ [NM] _ [NY] _ [NC] _ [ND] _ [OH] _ [OK]	_ [HI] _ [MS] _ [OR] _ [WY]	_ (ID) _ [MO] _ [PA] _ [PR]

(Use blank sheet, or copy and use additional copies of this sheet, as necessary.)

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if answer is "none" or "zero." If the transaction is an exchange offering, check this box n and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.	Aggregate Offering Price	Amount Aiready Sold
	Type of Security		
	Debt	\$	\$
	Equity	\$	s
	a Common a Preferred		
	Convertible Securities (including warrants)	\$ <u>2,500,000</u>	\$_2,500,000
	Partnership Interests	s	s
	Other (Specify)	\$	\$
	Total	\$ <u>2,500,000</u>	\$_2,500,000
	Answer also in Appendix, Column 3, if filing under ULOE.		
2.	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."	Number of Investors	Aggregate Dollar Amount of Purchases
	Accredited Investors	7	\$ <u>2,500,000</u>
	Non-accredited Investors		s
	Total (for filings under Rule 504 only)		\$
	Answer also in Appendix, Column 4, if filing under ULOE		3
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C – Question 1.	Type of Security	Dollar Amount Sold
	Type of offering		s
	Rule 505		
	Regulation A		\$
	Rule 504		\$
	Total		\$
4.	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the issuer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.		
	Transfer Agent's Fees	٥	s
	Printing and Engraving Costs	_	5
			£ 5000
	Legal Fees	•	\$ <u>5,000</u>
	Accounting Fees	0	\$
	Engineering Fees	0	s
	Sales Commissions (specify finders' fees separately)	D	s
	Other Expenses (identify)		s
	Total	=	\$ <u>5,000</u>

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

Issu Coll	• • • • • • • • • • • • • • • • • • • •	Signature SILLIAN No Tanner Title of Signer (Print or Type) Executive Vice President and Chi		Date November 6, 2007		
Issu Coll	ne of Signer (Print or Type)	Title of Signer (Print or Type)		November 6, 2007		
non-	• • • • • • • • • • • • • • • • • • • •	Signature Steuen N. Tanner	pam	1		
		· · · · · · · · · · · · · · · · · · ·		CARLO AL TO		
The	issuer has duly caused this notice to be signed undertaking by the issuer to furnish to the U.S. Seaccredited investor pursuant to paragraph (b)(2	securities and Exchange Commission, upo	n. If this notice in written reques	s filed under Rule 505, the t of its staff, the information	following s 1 furnished	signature constitutes by the issuer to any
		D. FEDERAL SIGNA	TURE			
	Total Payments Listed (column totals added)			= \$_	<u>2,495,000</u>	
	Column Totals		•	s	•	\$_2,495,000
				s	0	s
	Other (specify):			\$		2
	Working capital		0	\$	•	\$ <u>2,495,000</u>
	Repayment of indebtedness		O	s	0	\$
	Acquisition of other business (including the value that may be used in exchange for the assets or merger)	securities of another issuer pursuant to a	0	S	0	s
	Construction or leasing of plant buildings and		O	\$		\$
	Purchase, rental or leasing and installation of	nachinery and equipment	o	s		\$
	Purchase of real estate			\$	O	2
**	Salaries and fees		B	s	ם	s
٠,				Payments to Officers, Directors, & Affiliates		Payments To Others
4.	Indicate below the amount of the adjusted gross for each of the purposes shown. If the amount and check the box to the left of the estimate. If adjusted gross proceeds to the issuer set forth	for any purpose is not known, furnish an the total of the payments listed must equal	estimate I the			
5.						

END